Clinical observation on pathologic myopia CNV treated with intravitreal bevacizumab

AIM: To evaluate the efficacy and safety of intravitreal bevacizumab(Avastin)for choroidal neovascularization(CNV)in pathologic myopia(PM)by including optical coherence tomography(OCT), fluorescein angiography(FFA)and best-corrected visual acuity(BCVA). METHODS: Totally 42 eyes in 41 patients with PM CNV were divided into 2 groups randomly, experimental group(n=22)were assigned to receive intravitreal bevacizumab injections and take fufangxueshuantong capsule; control group(n=20)just took fufangxueshuantong capsule. Subjects were followed up every month after treatment. The efficacy and safety of two group were compared by ophthalmic evaluations including OCT, FFA, and BCVA. RESULTS: BCVA: BCVA in two groups was improved after 12 months. The mean number of treatments per eye, experimental group was 4.23±2.02 and control group was 1.95±1.90. There was significant difference(P